Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.50 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.50 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRAS | P01112 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24699869 | 0.96 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4B4GALT1 | |
| SCHEMBL22855653 | 0.96 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4B4GALT1 | |
| SCHEMBL15499416 | 0.94 | MAPK1 (0.55) | MAPK1LGALS8LGALS3LGALS4B4GALT1 | |
| SCHEMBL20985069 | 0.93 | MAPK1 (0.53) | MAPK1B4GALT1MEN1KMT2AHRAS | |
| SCHEMBL30980624 | 0.91 | MAPK1 (0.52) | MAPK1LGALS8LGALS3LGALS4B4GALT1 | |
| SCHEMBL24239904 | 0.89 | LMNA (0.52) | MAPK1B4GALT1MEN1KMT2AHRAS | |
| SCHEMBL8985399 | 0.88 | TGM2 (0.49) | LGALS8 | |
| SCHEMBL18875811 | 0.87 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4B4GALT1 | |
| SCHEMBL23992233 | 0.86 | MAPK1 (0.60) | MAPK1LGALS8LGALS3LGALS4B4GALT1 | |
| SCHEMBL2003046 | 0.86 | LMNA (0.50) | MAPK1LGALS8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015188194-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | MAPK1 3820/4885LGALS8 31/4885LGALS3 55/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | MAPK1 4769/4885LGALS8 21/4885LGALS3 25/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | MAPK1 3820/4885LGALS8 31/4885LGALS3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.